Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP7709260B2 - Fatigue reducing agent and food and drink composition for reducing fatigue - Google Patents
[go: Go Back, main page]

JP7709260B2 - Fatigue reducing agent and food and drink composition for reducing fatigue - Google Patents

Fatigue reducing agent and food and drink composition for reducing fatigue

Info

Publication number
JP7709260B2
JP7709260B2 JP2018144156A JP2018144156A JP7709260B2 JP 7709260 B2 JP7709260 B2 JP 7709260B2 JP 2018144156 A JP2018144156 A JP 2018144156A JP 2018144156 A JP2018144156 A JP 2018144156A JP 7709260 B2 JP7709260 B2 JP 7709260B2
Authority
JP
Japan
Prior art keywords
fatigue
reducing
food
reducing agent
physical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018144156A
Other languages
Japanese (ja)
Other versions
JP2020018215A (en
Inventor
吉武 馬場
隼 稲垣
孝宣 瀧原
貴之 越智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ito En Ltd
Original Assignee
Ito En Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ito En Ltd filed Critical Ito En Ltd
Priority to JP2018144156A priority Critical patent/JP7709260B2/en
Publication of JP2020018215A publication Critical patent/JP2020018215A/en
Priority to JP2024129570A priority patent/JP2024144721A/en
Application granted granted Critical
Publication of JP7709260B2 publication Critical patent/JP7709260B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Description

本発明は、食酢由来の酢酸を有効成分とする疲労感軽減剤に関し、特に就寝前の身体的疲労感を軽減することのできる疲労感軽減剤に関するものである。また、本発明は、当該疲労感軽減剤を含む疲労感軽減用飲食品組成物、とりわけ飲料の形態をとる疲労感軽減用飲食品組成物にも関する。 The present invention relates to a fatigue-reducing agent that contains acetic acid derived from vinegar as an active ingredient, and in particular to a fatigue-reducing agent that can reduce physical fatigue before going to bed. The present invention also relates to a food and drink composition for reducing fatigue that contains the fatigue-reducing agent, particularly a food and drink composition for reducing fatigue that takes the form of a beverage.

現代の日本社会においては、疲労や倦怠感を自覚する人が増えている。特に、近年はIT化・24時間社会化が進むにつれ、ストレスを受ける機会も多く、休息や睡眠をとっても疲労感が容易に回復しない症状に悩む人の増加が問題となっている。
疲労感には、身体的な疲労感だけでなく、精神的な疲労感、さらには身体的な疲労感と精神的な疲労感とが複合的に関与したものも存在すると考えられており、特に現代人で増えている疲労感は、睡眠の質の低下やストレスの増加がその一因となっているものと考えられている。しかし、現代社会において睡眠の質を高めるのは難しく、一方でストレスを解消するために運動を行うことが考えられるが、かえってさらなる身体的疲労を蓄積してしまうといった新たな問題が生まれている。
In modern Japanese society, the number of people who are aware of fatigue and lethargy is increasing. In particular, in recent years, as IT and 24-hour society have progressed, there are more opportunities for stress, and the number of people who suffer from symptoms in which fatigue does not easily recover even after resting or sleeping is increasing, which has become a problem.
It is believed that fatigue can be not only physical fatigue, but also mental fatigue, and even a combination of physical and mental fatigue. In particular, the increasing fatigue felt by modern people is thought to be partly due to poor sleep quality and increased stress. However, it is difficult to improve the quality of sleep in modern society, and while exercising can be considered a way to relieve stress, it actually creates new problems such as further accumulation of physical fatigue.

疲労感の軽減効果を標榜するものとして、医薬品、医薬部外品やサプリメント等が上市されているが、現代人にとっては、より自然な方法で疲労感を解消することが重要となっている。 There are many medicines, quasi-drugs, and supplements on the market that claim to reduce fatigue, but for modern people, it is important to find more natural ways to relieve fatigue.

食酢は抗疲労効果を有すると言われているが(例えば、特許文献1参照)、人において試験した報告は少なく、どのような疲労が軽減されるかについての十分な知見が存在しなかった。 Vinegar is said to have anti-fatigue effects (see, for example, Patent Document 1), but there have been few reports of testing it on humans, and there is not enough knowledge about what kind of fatigue it relieves.

特開2007-204445号公報JP 2007-204445 A

本発明は、疲労感軽減作用を有するものを見出し、それを有効成分とする疲労感軽減剤、および当該疲労感軽減剤を含む疲労感軽減用飲食品組成物を提供することを目的とする。 The present invention aims to discover a substance that has a fatigue-reducing effect, and to provide a fatigue-reducing agent that contains the substance as an active ingredient, and a food and beverage composition for reducing fatigue that contains the fatigue-reducing agent.

本発明者は上記問題を解決すべく研究を行った結果、食酢由来の酢酸が、疲労感軽減作用、とりわけ就寝前の身体的疲労感を軽減できることを見出し、本発明を完成させるに至った。
具体的には、本発明は以下のとおりである。
As a result of research conducted by the present inventors to solve the above problems, they discovered that acetic acid derived from vinegar has the effect of reducing fatigue, particularly the physical fatigue before going to bed, and thus completed the present invention.
Specifically, the present invention is as follows.

〔1〕 疲労感軽減剤であって、食酢由来の酢酸を有効成分とし、前記疲労感は就寝前の身体的疲労感を含む、疲労感軽減剤。
〔2〕 前記疲労感は起床後の精神的疲労感を含む、〔1〕に記載の疲労感軽減剤。
〔3〕 前記食酢は黒酢である、〔1〕または〔2〕に記載の疲労感軽減剤。
〔4〕 1日1回以上、酢酸に換算して1日当たり620mg以上投与される、〔1〕~〔3〕のいずれかに記載の疲労感軽減剤。
〔5〕 一週間以上連続して投与される、〔4〕に記載の疲労感軽減剤。
〔6〕 前記疲労感はVAS(Visual Analogue Scale)検査によって評価される、〔1〕~〔5〕のいずれかに記載の疲労感軽減剤。
〔7〕 疲労感を軽減するための飲食品組成物であって、〔1〕~〔6〕のいずれかに記載の疲労感軽減剤を含み、前記疲労感は就寝前の身体的疲労感を含む、疲労感軽減用飲食品組成物。
〔8〕 飲料の形態である、〔7〕に記載の疲労感軽減用飲食品組成物。
〔9〕 酢酸含有量が500~3500mgである、〔7〕または〔8〕に記載の疲労感軽減用飲食品組成物。
〔10〕 〔1〕~〔6〕のいずれかに記載の疲労感軽減剤または〔7〕~〔9〕のいずれかに記載の飲食品組成物を投与することを含む、疲労感軽減作用を発揮させる方法(医療行為を除く)であって、前記疲労感は就寝前の身体的疲労感を含む、方法。
[1] A fatigue reducing agent, comprising acetic acid derived from vinegar as an active ingredient, wherein the fatigue includes physical fatigue before going to bed.
[2] The fatigue reducing agent according to [1], wherein the fatigue includes mental fatigue after waking up.
[3] The fatigue reducing agent according to [1] or [2], wherein the vinegar is black vinegar.
[4] The fatigue reducing agent according to any one of [1] to [3], which is administered at least once a day in an amount of 620 mg or more per day calculated as acetic acid.
[5] The fatigue reducing agent according to [4], which is administered continuously for one week or more.
[6] The fatigue reducing agent according to any one of [1] to [5], wherein the fatigue is evaluated by a visual analogue scale (VAS) test.
[7] A food or drink composition for reducing fatigue, comprising the fatigue reducer according to any one of [1] to [6], wherein the fatigue includes physical fatigue before going to bed.
[8] The food and drink composition for reducing fatigue according to [7], which is in the form of a beverage.
[9] The food or drink composition for reducing fatigue according to [7] or [8], having an acetic acid content of 500 to 3,500 mg.
[10] A method (excluding medical procedures) for exerting a fatigue reducing effect, comprising administering a fatigue reducing agent according to any one of [1] to [6] or a food or beverage composition according to any one of [7] to [9], wherein the fatigue includes physical fatigue before going to bed.

本発明に係る疲労感軽減剤および疲労感軽減用飲食品組成物によれば、食酢由来の酢酸を有効成分とすることにより、手軽に摂取することが可能でありながら、疲労感を軽減することができ、とりわけ就寝前の身体的疲労感を軽減することができる。 The fatigue-reducing agent and food and beverage composition for reducing fatigue according to the present invention uses acetic acid derived from vinegar as an active ingredient, making it possible to easily ingest the agent and food and beverage composition for reducing fatigue, and in particular reducing physical fatigue before going to bed.

図1は、実施例飲料群およびプラセボ飲料群における身体的疲労感のVAS検査評価結果を表したグラフである。FIG. 1 is a graph showing the results of VAS test evaluation of physical fatigue in the example beverage group and the placebo beverage group. 図2は、実施例飲料群およびプラセボ飲料群における精神的疲労感のVAS検査評価結果を表したグラフである。FIG. 2 is a graph showing the results of the VAS test evaluation of mental fatigue in the example beverage group and the placebo beverage group.

〔疲労感軽減剤〕
本実施形態に係る疲労感軽減剤は、食酢由来の酢酸を有効成分とするものである。本実施形態により軽減される疲労感は、就寝前の身体的疲労感を含む。
[Fatigue Relief Agent]
The fatigue reducing agent according to this embodiment contains acetic acid derived from vinegar as an active ingredient. The fatigue reduced by this embodiment includes physical fatigue before going to bed.

ここで、本実施形態において、「疲労」とは、主に肉体的および精神的活動によって生じた独特の不快感と休養の願望を伴う身体活動能力や思考能力の減退状態をいう。「疲労感」とは、疲労が存在することを自覚する感覚をいい、多くの場合不快感と活動意欲の低下が認められる。
また、「身体的疲労感」とは、上記疲労の中でも特に身体の活動能力の減退状態があり、それを自覚している感覚をいう。かかる感覚は、「身体の疲れ」として評価できるほか、全体倦怠感、だるさ、脱力感等といった身体の活動意欲の低下としても評価することができる。
「就寝前の身体的疲労感」とは、就寝前30分以内に自覚される身体的疲労感をいうものとする。
In this embodiment, "fatigue" refers to a state of decreased physical activity and thinking ability accompanied by a unique discomfort caused mainly by physical and mental activity and a desire for rest. "Feeling of fatigue" refers to a sense of awareness of the presence of fatigue, and in many cases, discomfort and a decreased will to be active are observed.
"Physical fatigue" refers to the sense of being aware of a reduced ability to perform physical activities, among the above fatigues. Such a sense can be evaluated not only as "physical fatigue" but also as a decrease in the will to perform physical activities, such as general malaise, lethargy, or weakness.
"Physical fatigue before going to bed" refers to physical fatigue felt within 30 minutes before going to bed.

本実施形態に係る疲労感軽減剤は、運動負荷を受けた当日であって就寝前の身体的疲労感に対し、特に好適に適用することができる。ここで、運動負荷とは、上記身体的疲労感を付与する肉体的活動をいう。本実施形態の適用対象となる運動負荷は、例えば、カルボーネン法の計算式にもとづき、運動強度が50%以上(好ましくは50~70%)となる心拍数が10分以上(好ましくは30~60分程度)維持される程度の運動負荷であることが好ましい。また、運動負荷は、就寝前7~14時間の間に行われていることが好ましい。
ここで、運動負荷後の身体的疲労感は、通常、運動負荷からの時間経過とともに回復し、クレアチンキナーゼや乳酸等の各種疲労物質についても時間経過による代謝により減少し、さらに心拍、血流等も定常状態に近づくものと考えられている。しかし、本発明者らが得た知見によれば、一旦回復したと思われる疲労感が就寝前にぶり返すという事象が認められた。かかる事象に対し、本実施形態の疲労感軽減剤によれば、運動負荷後であって就寝前の身体的疲労感が軽減されるため、適用対象として特に好適である。
The fatigue reducing agent according to the present embodiment can be particularly suitably applied to the physical fatigue felt before going to bed on the day of exercise stress. Here, the exercise stress refers to physical activity that gives the above-mentioned physical fatigue. The exercise stress to which the present embodiment is applied is preferably an exercise stress that maintains a heart rate at which the exercise intensity is 50% or more (preferably 50 to 70%) for 10 minutes or more (preferably about 30 to 60 minutes) based on the calculation formula of the Karvonen method. In addition, the exercise stress is preferably performed within 7 to 14 hours before going to bed.
Here, it is believed that the physical fatigue after exercise usually recovers over time, and various fatigue substances such as creatine kinase and lactic acid are reduced by metabolism over time, and the heart rate, blood flow, etc. also approach a steady state. However, according to the findings of the present inventors, the fatigue that was thought to have been recovered from once returns before going to bed. In response to such a phenomenon, the fatigue reducing agent of the present embodiment reduces the physical fatigue after exercise and before going to bed, making it particularly suitable as an application subject.

本実施形態により軽減される疲労感は、起床後の精神的疲労感をさらに含むことが好ましい。
本実施形態において、「精神的疲労感」とは、上記疲労の中でも特に精神的活動能力の減退状態があり、それを自覚している感覚をいう。かかる感覚は、「精神的な疲れ」として評価できるほか、集中力・思考力の低下や感情の不安定化等としても評価することができる。さらに、精神的な疲労が身体的な疲労と複合化した状態となっている場合には、全体倦怠感、だるさ、脱力感等の身体の活動意欲の低下としても評価することもできる。
「起床後の精神的疲労感」とは、起床後30分以内に自覚される精神的疲労感である。
It is preferable that the feeling of fatigue that is reduced by this embodiment further includes a feeling of mental fatigue after waking up.
In this embodiment, "mental fatigue" refers to a sense of being aware of a state of decline in mental activity, particularly among the above fatigue. Such a sense can be evaluated as "mental fatigue," as well as a decline in concentration and thinking ability, emotional instability, and the like. Furthermore, when mental fatigue is combined with physical fatigue, it can also be evaluated as a decline in the will to be physically active, such as a general feeling of malaise, lethargy, or weakness.
"Mental fatigue after waking up" refers to mental fatigue felt within 30 minutes after waking up.

本実施形態の一態様により軽減される、起床後の精神的疲労感は、上記運動負荷を受けた翌朝の起床後における精神的疲労感を含むことがさらに好ましい。
運動負荷等により身体的な疲労感が蓄積すると、活動能力の減退や活動意欲の低下により、動きたくても動きづらい状態となってしまって精神的なストレスが蓄積し、身体的な疲労感と精神的な疲労感と複合化した状態に陥ってしまうことがある。精神的な疲労感だけであれば、その原因となるストレスを解消するために運動を行うことが考えられるが、身体的な疲労感と精神的な疲労感とが複合的に関与している場合、運動によりかえってさらなる疲労感を蓄積してしまうといった新たな問題が生じ得る。
本実施形態の好ましい一態様によれば、運動負荷を受けた翌朝の起床後における精神的疲労感をも好適に軽減することができる。
It is more preferable that the mental fatigue after waking up that is reduced by one aspect of this embodiment includes the mental fatigue after waking up the next morning following the exercise stress.
When physical fatigue accumulates due to exercise load, etc., the ability to move decreases and the will to be active decreases, making it difficult to move even if one wants to, which accumulates mental stress and can lead to a state in which physical fatigue and mental fatigue are combined. If it is only mental fatigue, it is possible to exercise to relieve the stress that causes it, but if physical fatigue and mental fatigue are combined, a new problem may arise in which exercise actually accumulates even more fatigue.
According to a preferred aspect of this embodiment, it is also possible to suitably reduce the sense of mental fatigue felt upon waking up the next morning following an exercise load.

ここで、精神的疲労感は、外部から受ける精神的ストレスの他、睡眠の質の低下もその一因と考えられている。本実施形態において起床後の精神的疲労感が軽減される作用機序は必ずしも明らかでないが、本実施形態に係る疲労感軽減剤は就寝前の身体的疲労感を軽減することができるため、これにより、睡眠の質が改善され、起床後の精神的疲労感が軽減される可能性が考えられる。ただし、本実施形態の好ましい一態様による、起床後の精神的疲労感の軽減効果は、かかる作用機序に限定されるものではない。 Here, mental fatigue is thought to be caused not only by external mental stress, but also by a decline in the quality of sleep. The mechanism by which mental fatigue after waking up is reduced in this embodiment is not entirely clear, but the fatigue-reducing agent of this embodiment can reduce physical fatigue before going to bed, which may improve sleep quality and reduce mental fatigue after waking up. However, the effect of reducing mental fatigue after waking up in a preferred embodiment of this embodiment is not limited to this mechanism of action.

上記疲労感は個人の主観的な感覚ではあるが、可能な限り客観的に評価することが好ましく、例えば、抗疲労臨床評価ガイドライン(日本疲労学会)に準拠して評価することができる。また、上記疲労感は、被投与者の感覚を数値化することで評価されることが好ましく、VAS(Visual Analogue Scale)検査によって評価されることが好ましい。より具体的には、VASに基づき身体的疲労感を評価する場合、0~10.0cmのスケールにおいて(通常、長さ10.0cmの線の上で)、身体的疲労感が全くない状態を「0」cm、経験しうる最大の身体的疲労感を「10.0」cmとし、特定の時点(運動直後、運動後の所定時間経過後、就寝前、起床後)で被投与者自らが感じる身体的疲労感を、0(全くない)~10.0(経験しうる最大の身体的疲労感)の範囲内で評価させる。かかるVASによれば、疲労等の症状とその回復の程度をパラメーターとして評価することが可能になる。 Although the fatigue sensation is a subjective feeling of an individual, it is preferable to evaluate it as objectively as possible, and for example, it can be evaluated in accordance with the Anti-Fatigue Clinical Evaluation Guidelines (Japan Society of Fatigue Science). In addition, the fatigue sensation is preferably evaluated by quantifying the sensation of the recipient, and is preferably evaluated by a VAS (Visual Analogue Scale) test. More specifically, when evaluating physical fatigue sensation based on a VAS, on a scale of 0 to 10.0 cm (usually on a line with a length of 10.0 cm), a state in which there is no physical fatigue at all is set to "0" cm, and the maximum physical fatigue that can be experienced is set to "10.0" cm, and the physical fatigue felt by the recipient at a specific time point (immediately after exercise, a certain time after exercise, before going to bed, and after waking up) is evaluated within the range of 0 (not at all) to 10.0 (maximum physical fatigue that can be experienced). Such a VAS makes it possible to evaluate symptoms such as fatigue and the degree of recovery from them as parameters.

本実施形態の効果を評価する場合、2群における評点(通常は平均値)の差異が有意な差異であるか否かについて、有意確率(p)を算出することにより評価することができる。なお有意確率pの算出は、統計学上で既知の方法、例えばt検定により行ってもよい。一般的に有意差はp<0.05(5%)であるとされるが、有意差を示唆する数値としてp≦0.1を基準として評価を行うこともできる。 When evaluating the effect of this embodiment, it is possible to evaluate whether the difference in the scores (usually the average values) between the two groups is a significant difference by calculating the significance probability (p). The significance probability p may be calculated by a method known in statistics, such as a t-test. Generally, a significant difference is considered to be p<0.05 (5%), but evaluation can also be performed using p≦0.1 as a criterion for a value suggesting a significant difference.

本実施形態に係る疲労感軽減剤の有効成分は、食酢由来の酢酸である。
上記食酢は、食酢品質表示基準により定義されるものであり、醸造酢および合成酢が含まれ、醸造酢には、米酢、米黒酢、大麦黒酢等の穀物酢;りんご酢、ぶどう酢等の果実酢;などがさらに含まれる。これらの中でも、黒酢(米黒酢および大麦黒酢)であることが好ましい。
本実施形態においては、有効量の酢酸を含むものであれば、食酢をそのまま有効成分として用いてもよく、食酢から粗精製した酢酸を用いてもよい。
The active ingredient of the fatigue reducing agent according to this embodiment is acetic acid derived from vinegar.
The above-mentioned vinegar is defined by the vinegar quality labeling standard, and includes brewed vinegar and synthetic vinegar, and brewed vinegar further includes grain vinegar such as rice vinegar, rice black vinegar, barley black vinegar, etc.; fruit vinegar such as apple vinegar, grape vinegar, etc. Among these, black vinegar (rice black vinegar and barley black vinegar) is preferable.
In this embodiment, vinegar may be used as an active ingredient as long as it contains an effective amount of acetic acid, or acetic acid that has been roughly purified from vinegar may be used.

本実施形態の疲労感軽減剤は、食酢由来の酢酸のみからなるものでも良いし、食酢由来の酢酸を製剤化したものでもよい。製剤化する場合は、水、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、液状、カプセル、粉末、顆粒、錠剤等の任意の剤形に製剤化することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味・矯臭剤等を用いることができる。また、疲労感軽減剤は、他の組成物(例えば、後述する飲食品組成物等)に配合して使用することができる。なお、本実施形態の疲労感軽減剤は、必要に応じて、疲労感軽減作用を有する他の成分等を、食酢由来の酢酸とともに配合して有効成分として用いることができる。 The fatigue reducing agent of the present embodiment may consist of only acetic acid derived from vinegar, or may be a formulation of acetic acid derived from vinegar. When preparing a formulation, it can be formulated into any dosage form such as liquid, capsule, powder, granule, tablet, etc., according to a conventional method using a pharma- ceutically acceptable carrier such as water, dextrin, cyclodextrin, or other optional auxiliary agent. In this case, for example, excipients, binders, disintegrants, lubricants, stabilizers, flavorings, odorants, etc. can be used as auxiliary agents. The fatigue reducing agent can also be used by blending it with other compositions (for example, food and beverage compositions described later). The fatigue reducing agent of the present embodiment can be used by blending other components having a fatigue reducing effect with acetic acid derived from vinegar as necessary as active ingredients.

本実施形態の疲労感軽減剤を製剤化した場合、食酢由来の酢酸の含有量は、特に限定されるものではなく、目的、投与方法、投与量等に応じて適宜設定することができる。 When the fatigue reducing agent of this embodiment is formulated, the content of acetic acid derived from vinegar is not particularly limited and can be set appropriately depending on the purpose, administration method, dosage, etc.

本実施形態に係る疲労感軽減剤の投与方法は、経口投与であることが好ましい。
疲労感軽減剤の投与回数等は、疲労感の症状に応じて適宜設定することができるが、例えば、投与回数は1日1回以上とすることが好ましい。投与量は、酢酸に換算して1日当たり500mg以上とすることが好ましく、620mg以上とすることが特に好ましい。投与量の上限は特に限定されないが、酢酸に換算して1日当たり3500mg以下とすることができる。
The method of administration of the fatigue reducing agent according to this embodiment is preferably oral administration.
The number of times of administration of the fatigue reducing agent can be appropriately set according to the symptoms of fatigue, but for example, the number of times of administration is preferably once or more per day. The dosage is preferably 500 mg or more per day, and more preferably 620 mg or more, calculated as acetic acid. The upper limit of the dosage is not particularly limited, but can be 3500 mg or less per day, calculated as acetic acid.

疲労感軽減剤の投与期間は、2日以上連続して投与することが好ましく、一週間以上連続して投与することが特に好ましい。投与のタイミングは、身体的疲労感の原因となる肉体的活動や運動負荷の後またはその最中のみならず、疲労感等の症候を予防する観点から、活動前であってもよい。例えば、身体的疲労感を生じせしめる運動負荷の前に、被投与者に予め疲労感軽減剤を投与することもできる。 The fatigue-reducing agent is preferably administered for two or more consecutive days, and particularly preferably for one or more consecutive days. The timing of administration may be after or during physical activity or exercise stress that causes physical fatigue, or may be before activity from the viewpoint of preventing symptoms such as fatigue. For example, the fatigue-reducing agent may be administered to the recipient in advance before exercise stress that causes physical fatigue.

以上述べた本実施形態に係る疲労感軽減剤によれば、就寝前の身体的疲労感を軽減することができ、好ましくは起床後の精神的疲労感をも軽減することができる。また、かかる疲労感軽減剤を投与することにより、疲労感(とりわけ就寝前の身体的疲労感)の軽減作用を発揮させる方法(医療行為を除く)とすることができる(本発明に係る疲労感軽減作用を発揮させる方法の一態様に該当)。 The fatigue reducing agent according to the present embodiment described above can reduce physical fatigue before going to sleep, and preferably also mental fatigue after waking up. Furthermore, administering such a fatigue reducing agent can be used as a method (excluding medical procedures) for exerting an effect of reducing fatigue (particularly physical fatigue before going to sleep) (corresponding to one aspect of the method for exerting an effect of reducing fatigue according to the present invention).

〔疲労感軽減用飲食品組成物〕
本実施形態に係る疲労感軽減用飲食品組成物は、上記実施形態に係る疲労感軽減剤を含むものである。本実施形態により軽減される疲労感は、就寝前の身体的疲労感を含む。
飲食品組成物の摂取方法、摂取回数、摂取量、摂取期間等は特に限定されないが、前述した疲労感軽減剤と同様であることが好ましい。
[Food and drink composition for reducing fatigue]
The food and drink composition for reducing fatigue according to this embodiment contains the fatigue reducing agent according to the above embodiment. The fatigue reduced by this embodiment includes physical fatigue before going to bed.
The method, frequency, amount, and period of ingestion of the food and drink composition are not particularly limited, but are preferably the same as those of the fatigue reducing agent described above.

ここで、飲食品とは、人の健康に危害を加えるおそれが少なく、通常の社会生活において、経口又は消化管投与により摂取されるものをいう。したがって、本実施形態における「飲食品」は、経口的に摂取される一般食品、健康食品(機能性飲食品)、保健機能食品(特定保健用食品,機能性表示食品,栄養機能食品)等を幅広く含むものである。本実施形態に係る飲食品は、当該飲食品またはその包装に、食酢由来の酢酸が有する疲労感軽減作用を表示することのできる飲食品であることが好ましく、保健機能食品(特定保健用食品,機能性表示食品,栄養機能食品)であることが特に好ましい。 Here, food and drink refers to those that are unlikely to be harmful to human health and are taken orally or by administration through the digestive tract in normal social life. Therefore, in this embodiment, "food and drink" broadly includes general foods taken orally, health foods (functional food and drink), health functional foods (foods for specified health uses, foods with functional claims, foods with nutrient functions), etc. Food and drink according to this embodiment is preferably a food and drink that can display the fatigue-reducing effect of acetic acid derived from vinegar on the food and drink or its packaging, and is particularly preferably a health functional food (foods for specified health uses, foods with functional claims, foods with nutrient functions).

飲食品組成物の形態は特に限定されないが、摂取の容易さから、飲料またはカプセルの形態であることが好ましく、飲料の形態であることが特に好ましい。飲料の中でも、酢飲料、栄養ドリンク、スポーツドリンク、果実飲料、野菜飲料、野菜果汁混合飲料、機能性飲料、炭酸飲料、乳性飲料、コーヒー飲料、茶飲料等を例示することができ、特に種々の生理効果を有し、健康に寄与する飲料として、酢飲料、栄養ドリンク、スポーツドリンク等とするならば、呈味がよく、疲労感軽減効果も期待されるため好ましい。
飲料の形態とする場合は、そのまま飲用することができる、いわゆるRTD(Ready to Drink)形態の飲料として提供できるほか、水などで希釈して飲料する、いわゆる濃縮タイプの飲料としても提供することができる。
The form of the food and drink composition is not particularly limited, but it is preferably in the form of a drink or capsule because of the ease of intake, and is particularly preferably in the form of a drink.Among the drinks, vinegar drinks, nutritional drinks, sports drinks, fruit drinks, vegetable drinks, mixed vegetable and fruit juice drinks, functional drinks, carbonated drinks, milk drinks, coffee drinks, tea drinks, etc. can be exemplified, and in particular, as drinks that have various physiological effects and contribute to health, vinegar drinks, nutritional drinks, sports drinks, etc. are preferred because they have good taste and are expected to reduce fatigue.
When provided in the form of a beverage, it can be provided as a so-called RTD (Ready to Drink) beverage that can be consumed as is, or it can be provided as a so-called concentrated type beverage that can be diluted with water or the like and consumed.

本実施形態に係る飲食品組成物の形態が、RTD形態の飲料である場合には、例えば、150~600mLまたは150~600g入り容器に1回当たりの摂取量を添加すると、短時間で効率的な摂取が可能となる。かかる容器として、例えば、500mLまたは500g入り容器、350mLまたは350g入り容器、200mL容器または200g入り容器などが例示される。
また、本実施形態に係る飲食品組成物における酢酸含有量は、1回当たりの摂取量を考慮し、1本または1個装あたり500~3500mgであることが好ましく、620~1000mgであることが特に好ましい。
When the food and drink composition according to this embodiment is in the form of an RTD beverage, for example, adding the amount per serving to a container containing 150 to 600 mL or 150 to 600 g allows efficient ingestion in a short period of time. Examples of such containers include containers containing 500 mL or 500 g, 350 mL or 350 g, and 200 mL or 200 g.
Furthermore, the acetic acid content in the food and beverage composition according to this embodiment is preferably 500 to 3,500 mg, and particularly preferably 620 to 1,000 mg, per bottle or individual package, taking into consideration the amount to be taken per serving.

本実施形態に係る飲食品組成物は、上記疲労感軽減剤のほか、飲食品の製造に用いられる一般的な食品素材を適宜添加することができる。かかる食品素材としては、各種糖質、甘味料、酸味料、食塩、乳化剤、増粘剤、香料、アミノ酸、果汁等が挙げられる。
糖質としては、蔗糖、異性化糖、グルコース、フラクトース、パラチノース、トレハロース、ラクトース、キシロース等の糖類;ソルビトール、キシリトール、エリスリトール、ラクチトール、パラチニット、還元水飴、還元麦芽糖水飴等の糖アルコール類;などが挙げられ、黒糖蜜等の糖蜜を用いてもよい。
甘味料としては、スクラロース、アスパルテーム、ステビア、アセスルファムカリウム等の高甘味度甘味料が挙げられる。
このほか、クエン酸、乳酸、リンゴ酸等の酸味料;蔗糖脂肪酸エステル、グリセリン脂肪酸エステル、レシチン等の乳化剤;カラギーナン、キサンタンガム、グァーガム、ペクチン、ローカストビーンガム等の増粘(安定)剤;レモン果汁、オレンジ果汁、ベリー系果汁等の果汁類等を添加してもよい。
さらに、これらの他にも、ビタミンA、ビタミンB類、ビタミンC、ビタミンD、ビタミンE等のビタミン類;カルシウム、鉄、マンガン、亜鉛等のミネラル類;などを添加することが可能である。
In addition to the fatigue reducing agent, general food ingredients used in the manufacture of foods and beverages can be appropriately added to the food and beverage composition according to this embodiment, such as various carbohydrates, sweeteners, acidulants, salt, emulsifiers, thickeners, flavorings, amino acids, fruit juices, etc.
Examples of carbohydrates include sugars such as sucrose, isomerized sugar, glucose, fructose, palatinose, trehalose, lactose, and xylose; sugar alcohols such as sorbitol, xylitol, erythritol, lactitol, palatinite, reduced starch syrup, and reduced maltose syrup; and molasses such as brown sugar syrup may also be used.
Sweeteners include high-intensity sweeteners such as sucralose, aspartame, stevia, and acesulfame potassium.
In addition, acidulants such as citric acid, lactic acid, malic acid, etc.; emulsifiers such as sucrose fatty acid esters, glycerin fatty acid esters, lecithin, etc.; thickeners (stabilizers) such as carrageenan, xanthan gum, guar gum, pectin, locust bean gum, etc.; and fruit juices such as lemon juice, orange juice, berry juice, etc. may be added.
In addition to these, it is possible to add vitamins such as vitamin A, B vitamins, vitamin C, vitamin D, and vitamin E; minerals such as calcium, iron, manganese, and zinc; and the like.

本実施形態に係る飲食品組成物は、常法に従って製造することができる。例えば、飲料の形態であれば、食酢をそのまま、または食酢から粗精製した酢酸を添加し、さらにそのほかの食品素材を適宜添加して飲料原液を調製し、その後、殺菌し容器充填すればよい。
殺菌方法としては、気流式殺菌、高圧殺菌、加熱殺菌などを挙げることができる。加熱殺菌する場合には、例えば、110~130℃、さらには115~125℃で殺菌することができる。
容器としては、紙容器、PETボトル、缶(アルミニウム、スチール)、瓶(ガラス)、レトルトパウチ等が挙げられる。
The food and drink composition according to the present embodiment can be produced according to a conventional method. For example, in the form of a beverage, vinegar as is or acetic acid roughly refined from vinegar is added, and other food ingredients are appropriately added to prepare a beverage concentrate, which is then sterilized and filled into a container.
Sterilization methods include airflow sterilization, high-pressure sterilization, heat sterilization, etc. When heat sterilization is performed, the sterilization temperature can be, for example, 110 to 130°C, or further 115 to 125°C.
Examples of containers include paper containers, PET bottles, cans (aluminum, steel), bottles (glass), and retort pouches.

以上述べた本実施形態に係る疲労感軽減用飲食品組成物によれば、手軽に摂取することのできる飲食品組成物により、就寝前の身体的疲労感を軽減することができ、好ましくは起床後の精神的疲労感をも軽減することができる。また、かかる飲食品組成物を摂取させることにより、疲労感(とりわけ就寝前の身体的疲労感)の軽減作用を発揮させる方法(医療行為を除く)とすることができる(本発明に係る疲労感軽減作用を発揮させる方法の一態様に該当)。 According to the food and beverage composition for reducing fatigue according to the present embodiment described above, the food and beverage composition can be easily ingested, thereby reducing physical fatigue before going to sleep, and preferably also reducing mental fatigue after waking up. Furthermore, ingesting such a food and beverage composition can be used as a method (excluding medical procedures) for exerting an effect of reducing fatigue (particularly physical fatigue before going to sleep) (corresponding to one aspect of the method for exerting an effect of reducing fatigue according to the present invention).

以下、製造例、試験例等を示すことにより本発明をさらに詳細に説明するが、本発明は下記の製造例、試験例等に何ら限定されるものではない。 The present invention will be explained in more detail below by showing manufacturing examples, test examples, etc., but the present invention is not limited to the following manufacturing examples, test examples, etc.

〔製造例〕実施例飲料およびプラセボ飲料の製造
表1に示す配合の飲料原液を調製し、加熱殺菌して200mL紙パックに充填し、2種類の黒酢飲料(実施例飲料およびプラセボ飲料)を製造した。
なお、実施例飲料においては黒酢(横井醸造工業社製,商品名「玄米黒酢No.2」)を用い、一方プラセボ飲料においては当該黒酢から酢酸を除去したもの(8倍濃縮酢酸低減黒酢)を同等量配合し香味等が実施例飲料と同等となるように調整した。
[Production Example] Production of Example Beverage and Placebo Beverage A beverage concentrate having the composition shown in Table 1 was prepared, heat sterilized, and filled into 200 mL paper cartons to produce two types of black vinegar beverages (Example beverage and placebo beverage).
In the example beverage, black vinegar (manufactured by Yokoi Brewery Co., Ltd., product name "Brown Rice Black Vinegar No. 2") was used, while in the placebo beverage, an equal amount of the black vinegar from which the acetic acid had been removed (8-fold concentrated black vinegar with reduced acetic acid) was blended, and the flavor and other properties were adjusted to be equivalent to those of the example beverage.

〔試験例〕黒酢飲料摂取による疲労感軽減効果の検証
上記製造例で得られた実施例飲料およびプラセボ飲料を用い、以下のようにして疲労感軽減効果を検証した。なお、運動負荷にはエルゴメーター(エアロバイク(登録商標)ai,コンビ社製)を用い、身体的疲労感および精神的疲労感の軽減作用の評価には自己評価尺度であるVAS(Visual Analog Scale)を用いた。
[Test Example] Verification of the effect of black vinegar beverage intake on reducing fatigue The example beverage and placebo beverage obtained in the above production example were used to verify the effect of reducing fatigue as follows. An ergometer (AERO BIKE (registered trademark) ai, Combi Corporation) was used for exercise load, and a self-assessment scale, VAS (Visual Analog Scale), was used to evaluate the effect of reducing physical and mental fatigue.

無作為に選抜された健常な成人男女19名(39.84±3.93歳)を被験者とした。なお、被験者は、過去1年間習慣的に運動をしていない方とし、運動が週に1回以下であることを「習慣的に運動をしていない」目安とした。
被験者全員を無作為にA群およびB群の2群に分け、実施例飲料を摂取する試験とプラセボ飲料を摂取する試験との合計2回の試験を実施した(クロスオーバー試験)。被験者は、200mLの実施例飲料(酢酸量:659.4mg/本)またはプラセボ飲料(同59.0mg/本)を、1日1本、自由なタイミングで摂取させた。
Nineteen randomly selected healthy adult men and women (39.84±3.93 years old) were used as subjects. Subjects were required to have not habitually exercised in the past year, and exercising once a week or less was defined as "not habitually exercising."
All subjects were randomly divided into two groups, Group A and Group B, and a total of two tests were conducted, one in which subjects consumed the example beverage and one in which subjects consumed a placebo beverage (crossover test). Subjects consumed one 200 mL bottle of the example beverage (acetic acid content: 659.4 mg/bottle) or one placebo beverage (acetic acid content: 59.0 mg/bottle) per day at their own discretion.

疲労感軽減作用の確認試験は次のようなスケジュールで実施した(表2参照)。
(1)A群には実施例飲料を、B群にはプラセボ飲料を、それぞれ1週間摂取させた(200mL/1本,1日1回1本の自由摂取,各回の摂取タイミングは起床~就寝まで任意の間で被験者の任意とした。)。
(2)摂取期間後の運動負荷試験
(2-1)強度60%の運動負荷を50分間実施
(2-2)運動直後の疲労感調査(VAS)
(2-3)運動60分後の疲労感調査(VAS)
(2-4)運動7~14時間後であって就寝前30分以内の疲労感調査(VAS)
(2-5)起床後30分以内の疲労感調査(VAS)
(3)実施例飲料およびプラセボ飲料を摂取させない期間(ウォッシュアウト期間)を1週間設けた。
(4)A群およびB群を入れ替え(A群:プラセボ飲料,B群:実施例飲料)、(1)および(2)の試験を実施(クロスオーバー試験)。
The test to confirm the effect of reducing fatigue was carried out according to the following schedule (see Table 2).
(1) Group A was administered the example beverage, and Group B was administered a placebo beverage for one week (200 mL/bottle, one bottle per day, at the discretion of the subject, at any time between waking up and going to bed).
(2) Exercise stress test after the intake period (2-1) Exercise stress at 60% intensity for 50 minutes (2-2) Fatigue sensation survey (VAS) immediately after exercise
(2-3) Fatigue sensation survey after 60 minutes of exercise (VAS)
(2-4) Fatigue sensation survey (VAS) 7 to 14 hours after exercise and within 30 minutes before going to bed
(2-5) Survey on fatigue within 30 minutes after waking up (VAS)
(3) A one-week period (washout period) was provided during which the subject was not allowed to take the example beverage or the placebo beverage.
(4) Group A and Group B were switched (Group A: placebo beverage, Group B: example beverage), and tests (1) and (2) were conducted (crossover test).

運動負荷は、エルゴメーターを用いて行い、エアロバイク(登録商標)の運動強度は60%に設定した。この条件は有酸素運動と無酸素運動の境界域であるAT(Anaerobic Threshold:嫌気性代謝閾値)付近の運動を想定したものである。よって、軽度の運動のみならず日常生活の労作も評価の対象とした条件である。なお、試験はカルボーネン法により運動強度60%となるよう目標心拍数を設定し心拍数一定条件で実施した。より具体的には、目標心拍数={(220-年齢)-安静時心拍数}×運動強度(0.6)+安静時心拍数の計算式において運動強度が60%となる目標心拍数を設定した。 Exercise load was performed using an ergometer, and the exercise intensity of the Aerobike (registered trademark) was set to 60%. This condition assumes exercise near the AT (Anaerobic Threshold), which is the boundary between aerobic exercise and anaerobic exercise. Therefore, this condition is designed to evaluate not only mild exercise but also everyday life labor. The test was performed under constant heart rate conditions, with the target heart rate set to achieve 60% exercise intensity using the Karvonen method. More specifically, the target heart rate was set to achieve 60% exercise intensity using the formula: target heart rate = {(220 - age) - resting heart rate} x exercise intensity (0.6) + resting heart rate.

本試験例におけるVAS検査は、被験者が、特定の時点(運動直後,運動60分後,就寝前,起床後)で「身体の疲れはありますか?」および「精神的な疲れはありますか?」との問いに対し、全くない状態を0.0cm、経験しうる最大の身体的疲労感(または精神的疲労感)を10.0cmとし、0.0cm~10.0cmの線分上に被験者自身の状態を記入させることで行った。VAS検査の評価には、被験者が記入した線分上の位置を定規により測定し、小数点第一まで計測した数値を採用した。 In this test example, the VAS test was conducted by having the subject write their own state on a line between 0.0cm and 10.0cm in response to the questions "Are you physically tired?" and "Are you mentally tired?" at specific points (immediately after exercise, 60 minutes after exercise, before going to bed, and after waking up), with 0.0cm representing a state of complete absence and 10.0cm representing the maximum physical (or mental) fatigue that can be experienced. To evaluate the VAS test, the position on the line written by the subject was measured with a ruler, and the value measured to the first decimal point was used.

実施例飲料を摂取した場合とプラセボ飲料を摂取した場合とのそれぞれについて、上記特定の時点のVAS法評価結果の数値を全被験者について集計し、平均値を算出した。また、これらの平均値の差異が有意な差異であるか否かについて、有意確率(p)を算出することにより評価した。なお、有意確率pは、SPSS14.0を使用しt検定を行うことで算出した。判断基準としては、p≦0.05を有意差ありとし、p≦0.1を有意傾向ありとして、評価を行った。
結果を図1および図2に示す。
The numerical values of the VAS evaluation results at the above specific time points for each of the cases where the example beverage was consumed and the placebo beverage was consumed were tabulated for all subjects, and the average value was calculated. In addition, whether the difference between these average values was significant or not was evaluated by calculating the significance probability (p). The significance probability p was calculated by performing a t-test using SPSS14.0. The evaluation was performed with the following criteria: p≦0.05 was considered to be a significant difference, and p≦0.1 was considered to be a significant tendency.
The results are shown in Figures 1 and 2.

(結果・考察)
身体的疲労感について、就寝前の身体疲労感は、プラセボ飲料群のVAS結果の平均が4.0であるのに対し、実施例飲料群では3.0であった。両群の有意確率p=0.027であったことから、就寝前の身体疲労感は実施例飲料群において有意に軽減されていると認められた。ここで、プラセボ飲料群においては、運動負荷60分後(VAS結果平均値:3.2)と比べて就寝前(同4.0)の値が増えており、身体的疲労感が就寝前にぶり返すという事象が認められたが、実施例飲料群においてはぶり返しが観察されなかった。
(Results/Discussion)
Regarding physical fatigue, the average VAS score of the placebo group was 4.0, while that of the example group was 3.0. Since the significance probability of both groups was p=0.027, it was recognized that the physical fatigue before going to bed was significantly reduced in the example group. Here, in the placebo group, the value before going to bed (average VAS score: 4.0) was higher than that 60 minutes after exercise load (average VAS score: 3.2), and the phenomenon of physical fatigue returning before going to bed was observed, but no recurrence was observed in the example group.

また、精神的疲労感について、起床後の精神的疲労感は、プラセボ飲料群(VAS結果平均値:1.4)と実施例飲料群(同0.9)との両群の有意確率p=0.093であり、起床後の精神的疲労感が実施例飲料群において軽減されている傾向が認められた。 In addition, regarding mental fatigue, the significance probability for the mental fatigue after waking up in both the placebo beverage group (mean VAS result: 1.4) and the example beverage group (0.9) was p=0.093, indicating a tendency for mental fatigue after waking up to be reduced in the example beverage group.

本発明によれば、手軽に摂取することが可能でありながら、疲労感を軽減することができ、とりわけ就寝前の身体的疲労感を軽減することができる。 The present invention makes it possible to easily ingest the product while reducing fatigue, particularly physical fatigue before going to bed.

Claims (8)

疲労感軽減剤であって、食酢由来の酢酸を有効成分とし、前記疲労感は、運動負荷7~14時間後であって就寝前の身体的疲労感を含
前記運動負荷7~14時間後であって就寝前の身体的疲労感は、運動負荷60分後の身体的疲労感より大きく、
前記疲労感軽減剤は、1日1回以上、1週間以上連続して投与され、酢酸に換算して1日当たり500mg以上投与される、
疲労感軽減剤。
A fatigue reducing agent, comprising acetic acid derived from vinegar as an active ingredient, the fatigue including physical fatigue 7 to 14 hours after exercise load and before going to bed;
The sense of physical fatigue 7 to 14 hours after the exercise load and before going to bed is greater than the sense of physical fatigue 60 minutes after the exercise load,
The fatigue reducing agent is administered at least once a day for at least one week continuously, and at an amount of at least 500 mg per day calculated as acetic acid.
Fatigue reducer.
前記疲労感は、前記運動負荷の翌日の起床後の精神的疲労感を含む、請求項1に記載の疲労感軽減剤。 The fatigue reducing agent according to claim 1 , wherein the fatigue includes mental fatigue after waking up on the day following the exercise load . 前記食酢は黒酢である、請求項1または2に記載の疲労感軽減剤。 The fatigue reducing agent according to claim 1 or 2, wherein the vinegar is black vinegar. 酢酸に換算して1日当たり620mg以上投与される、請求項1~3のいずれか一項に記載の疲労感軽減剤。 The fatigue reducing agent according to any one of claims 1 to 3, wherein the agent is administered in an amount of 620 mg or more per day in terms of acetic acid. 前記疲労感はVAS(Visual Analogue Scale)検査によって評価される、請求項1~のいずれか一項に記載の疲労感軽減剤。 The fatigue reducing agent according to any one of claims 1 to 4 , wherein the fatigue is evaluated by a visual analogue scale (VAS) test. 疲労感を軽減するための飲食品組成物であって、請求項1~のいずれか一項に記載の疲労感軽減剤を含み、前記疲労感は、運動負荷7~14時間後であって就寝前の身体的疲労感を含む、疲労感軽減用飲食品組成物であって、
前記運動負荷7~14時間後であって就寝前の身体的疲労感は、運動負荷60分後の身体的疲労感より大きく、
前記疲労感軽減用飲食品組成物は、1日1回以上、1週間以上連続して摂取され、酢酸に換算して1日当たり500mg以上摂取される、
疲労感軽減用飲食品組成物。
A food and drink composition for reducing fatigue, comprising the fatigue-reducing agent according to any one of claims 1 to 5 , wherein the fatigue includes physical fatigue 7 to 14 hours after exercise and before going to bed,
The sense of physical fatigue 7 to 14 hours after the exercise load and before going to bed is greater than the sense of physical fatigue 60 minutes after the exercise load,
The food and drink composition for reducing fatigue is ingested at least once a day for at least one week in a row, and is ingested at 500 mg or more per day in terms of acetic acid.
A food and drink composition for reducing fatigue.
飲料の形態である、請求項に記載の疲労感軽減用飲食品組成物。 The food or beverage composition for reducing fatigue according to claim 6 , which is in the form of a beverage. 1回当たりの摂取量として前記酢酸を500~3500mg含有する、請求項またはに記載の疲労感軽減用飲食品組成物。 8. The food and drink composition for reducing fatigue according to claim 6 or 7 , which contains 500 to 3,500 mg of acetic acid per serving.
JP2018144156A 2018-07-31 2018-07-31 Fatigue reducing agent and food and drink composition for reducing fatigue Active JP7709260B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018144156A JP7709260B2 (en) 2018-07-31 2018-07-31 Fatigue reducing agent and food and drink composition for reducing fatigue
JP2024129570A JP2024144721A (en) 2018-07-31 2024-08-05 Fatigue reducing agent and food and drink composition for reducing fatigue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018144156A JP7709260B2 (en) 2018-07-31 2018-07-31 Fatigue reducing agent and food and drink composition for reducing fatigue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024129570A Division JP2024144721A (en) 2018-07-31 2024-08-05 Fatigue reducing agent and food and drink composition for reducing fatigue

Publications (2)

Publication Number Publication Date
JP2020018215A JP2020018215A (en) 2020-02-06
JP7709260B2 true JP7709260B2 (en) 2025-07-16

Family

ID=69589047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018144156A Active JP7709260B2 (en) 2018-07-31 2018-07-31 Fatigue reducing agent and food and drink composition for reducing fatigue
JP2024129570A Pending JP2024144721A (en) 2018-07-31 2024-08-05 Fatigue reducing agent and food and drink composition for reducing fatigue

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024129570A Pending JP2024144721A (en) 2018-07-31 2024-08-05 Fatigue reducing agent and food and drink composition for reducing fatigue

Country Status (1)

Country Link
JP (2) JP7709260B2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007204445A (en) * 2006-02-03 2007-08-16 Mitsukan Group Honsha:Kk Anti-fatigue composition
JP5066346B2 (en) * 2006-07-11 2012-11-07 株式会社健康家族 Composition for preventing and / or treating symptoms of menstrual pain and / or premenstrual syndrome
JP6352029B2 (en) * 2014-04-04 2018-07-04 日本メナード化粧品株式会社 Anti-fatigue
JP2018014912A (en) * 2016-07-26 2018-02-01 公立大学法人大阪市立大学 Food composition and method for providing food composition
JP7069538B2 (en) * 2016-12-05 2022-05-18 マルボシ酢株式会社 Vinegar-containing beverage composition

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
デサントスポーツ科学, 1994, Vol. 15, pp. 246-251
デサントスポーツ科学, 1998, Vol. 19, pp. 59-68
多山賢二, 生活習慣病に及ぼす食酢の効果, 日本釀造協會雜誌, 20021015, 第97巻、第10号, 693-699頁
大阪教育大学紀要 第IV部門, 2012, Vol. 60, No. 2, pp. 59-68
日本釀造協會雜誌, 1976, Vol. 71, No. 5, pp. 330-333
柳田藤治, 酢の機能性について, 日本釀造協會雜誌, 19900315, 第85巻、第3号, 134-141

Also Published As

Publication number Publication date
JP2024144721A (en) 2024-10-11
JP2020018215A (en) 2020-02-06

Similar Documents

Publication Publication Date Title
EP2539312B1 (en) Nutritional composition
TWI488639B (en) Compositions containing turmeric extract and slices of turmeric extract
JP3018053B2 (en) Food and drink
US20240398734A1 (en) Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis
EP1609375B1 (en) Glycine-containing food and use thereof
CN107624068B (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
EP2627196B1 (en) Dairy based smoothie for stimulating growth in children
JP5687423B2 (en) Alcohol fatigue improver
US20110136909A1 (en) Method for suppressing excessive appetite
Hayward et al. Nutritional needs of patients with malignancies of the head and neck
CN106470691B (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
JP7709260B2 (en) Fatigue reducing agent and food and drink composition for reducing fatigue
JP2022100719A (en) Composition for improving working memory in cognitive functions
JP2011153125A (en) Autonomic control agent containing pseudo-leaf of asparagus as active ingredient
KR20090045721A (en) Sleep disorders composition
JP2018201487A (en) Composition for recovery from fatigue and / or prevention of fatigue accumulation
JP2021100421A (en) Composition for improving liver function, and food composition for improving liver function
JP2018095580A (en) Anti-anxiety composition
JP7110418B2 (en) Agent for preventing/improving muscle fatigue, etc. containing hydrogen, and food/beverage composition
TWI879838B (en) Uses of the fermented extract of fresh leaves of evergreen daylily
US20250049749A1 (en) Composition for improving sleep quality or controlling autonomic nervous system
US20240261217A1 (en) Nutraceutical gummy compositions and method of preventing alcohol overconsumption symptoms
JP2025154148A (en) Drinks containing citrulline and GABA
JP2009155291A (en) Hair growth preventive for stress-related hair loss prevention
JP2026009568A (en) Composition for improving male menopausal disorders such as erectile dysfunction (ED), and medicines, foods and beverages containing the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221130

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230113

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230117

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230331

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250704

R150 Certificate of patent or registration of utility model

Ref document number: 7709260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150